June 3, 2019

A Belgian cellular therapy company has announced data from a phase 2a clinical trial of a therapy for an incurable liver condition.

Promethera Biosciences SA is working on a product called HepaStem that takes liver stem cells, expands them in the laboratory and gives them via IV to patients with a liver condition known as acute-on-chronic liver failure (ACLF). The stem cells migrate through the blood and settle in the liver, supporting regeneration.

Today, the only treatment for ACLF is a liver transplant. “Looks like the data is good and showing that the dosing protocol is safe,” said Scott Jones, Vice President, Scientific Affairs, at BioBridge Global.

“Preliminarily, the data is showing liver function improvement. Still early to say what the true effect is, but it looks very promising.”

May 27, 2019

Researchers in India are looking into stem cell proteins involved in the development of tumors realted to blood cancers, according to a recent study in the Journal of Blood.

Scientists knew that a protein known as p53 suppresses the development of tumors. But just 11% of the cancers that develop in the blood-forming bone marrow have a mutation in the gene that forms p53.

“The mechanism of how these leukemias exist in people with a normal p53 gene is not well defined,” said Scott Jones, Vice President, Scientific Affairs, at BioBridge Global.

So the researchers looked at a protein called Asrij that exists in blood-forming stem cells. They found that Asrtij (which is Sanskrit for “blood”) is abnormally expressed in leukemia and lymphoma, opening the way for destruction of the cancer-fighting p53 protein.

May 20, 2019

One of the nation’s largest charitable foundations has increased its investment in stem cell therapy to $150 million with its latest donation.

The New York-based Starr Foundation recently gave $50 million – on top of previous gifts totaling $100 million – to the Tri-Institutional Stem Cell Initiative, which is made up of researchers at Memorial Sloan Kettering Cancer Center, the Rockefeller University and Weill Cornell Medicine.

The grant was reported in Crain’s New York Business newspaper.

Breaking down acronyms with the experts who work with them day in and day out
May 13, 2019

Rogelio Zamilpa, Director of Cord Blood, and Jessica Raley, Director of the Center for Apheresis and Therapeutic Services, oversee the cord blood program, marrow, and peripheral blood stem cell collection centers at GenCure. They answer the question “What are PBSCs?”

What are PBSCs?

PBSCs stand for peripheral blood stem cells. PBSCs come from peripheral blood, or the blood circulating in your body.

PBSCs are given to patients who need a stem cell transplant because they are battling a blood disorder or cancer such as leukemia or lymphoma. They work by treating and regenerating a patient’s blood and immune system. PBSCs are easier to collect than bone marrow or cord blood, which are the other stem cell sources for regeneration of blood and immune cells.

May 6, 2019

This year’s Alamo Regional Science & Engineering Fair was March 1-3 at St. Mary's University. The fair is a competition for junior and senior high school kids from 32 counties around San Antonio, and it is sponsored by the Alamo Regional Academy of Science and Engineering.

This year, 10 judges from BioBridge Global reviewed more than 200 projects in four hours. The team selected the top three projects that represent our ASPIRE core values and support our mission of saving and enhancing lives through the healing power of human cells and tissue.

These are the projects of the BioBridge Global award recipients for 2019: